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Background
Clopidogrel pre-treatment significantly improves outcome in patients undergoing PCI; however, efficacy of an in-lab loading strategy before PCI after coronary angiography versus routine pre-load has not been fully characterized.
Methods
A total of 409 patients (39% with acute coronary syndrome) were randomized to receive a 600-mg clopidogrel loading dose 4 to 8 h before PCI (pre-load group, n ϭ 204) or a 600-mg loading dose given in the catheterization lab after coronary angiography, but prior to PCI (in-lab group, n ϭ 205). Primary end point was 30-day incidence of major adverse cardiac events: cardiac death, myocardial infarction (MI), or unplanned target vessel revascularization.
Results
There was no significant difference in primary end point between the 2 randomization arms (8.8% in-lab vs. 10.3% pre-load; p ϭ 0.72); this was mainly driven by periprocedural MI (8.8% vs. 9.3%, p ϭ 0.99). No increased risk of bleeding or vascular complications was observed in the pre-load arm (5.4% vs. 7.8%; p ϭ 0.42). As determined by the VerifyNow assay (Accumetrics, San Diego, California), patients in the in-lab group showed higher platelet reactivity during PCI and 2 h after intervention versus those in the pre-load arm (p Յ 0.043). Clopidogrel loading before percutaneous coronary intervention (PCI) can significantly improve clinical outcome; recent studies show that a 600-mg clopidogrel load given Ͼ2 h prior to the procedure achieves better clinical results compared to a 300-mg dose (1) . Pharmacokinetic evidence indicates that 600-mg clopidogrel achieves maximal platelet inhibition within 2 h after drug administration, whereas the conventional 300 mg will require longer than 12 h (2-4).
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The CREDO (Clopidogrel for the Reduction of Events During Observation) trial demonstrated a time dependence of the clinical benefit with the 300-mg dose utilized in the study, with at least 15 h of pre-treatment required to significantly decrease adverse events (5). Furthermore, data from the ISAR-REACT (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment) study (6) , which utilized a routine 600-mg clopidogrel loading dose given Ն2 h prior to PCI, indicate that this approach abolishes time-dependent differences in 30-day major adverse cardiac events (MACE) related to pre-treatment duration (2 to 3 h vs. 3 to 6 h vs. 6 to 12 h vs. Ͼ12 h).
Given the common practice of performing PCI at the same setting as diagnostic coronary angiography, many centers routinely pre-load with clopidogrel (at variable dosing) all patients undergoing coronary angiography, whereas others prefer to complete diagnostic angiography, assess the indication for PCI (vs. coronary bypass or medical therapy), and then administer clopidogrel in the laboratory before intervention. However, the former strategy might increase bleeding risk in patients needing urgent surgical revascularization; direct in-laboratory (in-lab) loading after diagnostic angiography may help avoid these risks, but it is unknown whether it would provide adequate antiplatelet effect and similar protection from periprocedural ischemic complications compared with pre-treatment given several hours before the procedure.
Thus, the ARMYDA (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study group (1,7-11) performed a multicenter, randomized, controlled trial comparing these 2 treatment options: ARMYDA-5 PRELOAD, evaluating safety and effectiveness of a strategy of 600-mg clopidogrel load given in the catheterization laboratory at the time of PCI after diagnostic coronary angiography versus routine 600-mg pre-treatment.
Methods
Study population and design. The design of the study is illustrated in Figure 1 . ARMYDA-5 PRELOAD is a spontaneous, unfunded clinical trial performed in 3 Italian institutions. Inclusion criteria were clopidogrel-naive patients with a variety of ischemic coronary syndromes, including non-ST-segment elevation acute coronary syndrome (NSTE-ACS), undergoing coronary angiography. Exclusion criteria were: primary PCI for acute myocardial infarction; NSTE-ACS with high-risk features warranting emergency coronary angiography within 2 h; contraindications to antithrombotic or antiplatelet therapy (including platelet count Ͻ70 ϫ 10 9 /l); patients at high risk of bleeding; and treatment with clopidogrel within 10 days from randomization. A total of 536 patients fulfilling the enrollment criteria were randomized to a 600-mg clopidogrel loading dose to be given 4 to 8 h before diagnostic cardiac catheterization (n ϭ 267) or in the catheterization laboratory at the time of PCI following diagnostic angiography (n ϭ 269). Eligible patients were assigned to the allocation arm using an electronic spreadsheet indicating the group assignment by random numbers; randomization blocks were created and distributed to the 3 centers. After angiography, 127 patients (24%, 63 in the pre-load arm and 64 in the in-lab arm) who did not receive PCI were excluded from the study (72 were treated medically and 55 with elective coronary artery bypass surgery [CABG]); thus, 409 patients with significant coronary disease suitable for percutaneous intervention were enrolled and represent the study population; 204 patients belonged to the pre-load arm and 205 to the in-lab arm. Study drug administration was performed on an open-label basis without blinding; by design, PCI was performed immediately after diagnostic angiography. In patients with ACS, cardiac catheterization was generally performed within 12 h from admission.
Interventions were performed with standard technique, as previously described (1, 7, 10) ; all patients were pre-treated with aspirin (100 mg/day); after PCI, they received aspirin (100 mg/day) indefinitely and were continued on clopidogrel (75 mg/day) for at least 1 month (12 months in those with ACS or receiving drug-eluting stents), irrespective of randomization assignment.
In all patients, blood samples were drawn before and at 8 and 24 h after the procedure to detect creatine kinase-MB (mass) and troponin-I (mass) levels; further measurements were obtained in case of post-procedural symptoms suggestive of myocardial ischemia. Measurements of creatine kinase-MB and troponin-I were performed using the Access 2 Immunochemiluminometric assay (Beckman Coulter, Borea, California) (12) . Upper normal limits were defined as the 99th percentile of normal population with a total imprecision of Ͻ10%, according to Joint European Society of Cardiology/ American College of Cardiology guidelines (13) . Normal limits were Յ3.6 ng/ml for creatine kinase-MB and Յ0.034 ng/ml for troponin-I.
In all patients, platelet reactivity after clopidogrel was evaluated at the time of randomization (baseline value), in the catheterization laboratory at the time of PCI, and at 2, 8, and 24 h after intervention by the VerifyNow P2Y 12 assay (Accumetrics, San Diego, California). VerifyNow P2Y 12 is a rapid, cartridge-based assay specifically measuring direct effects of clopidogrel on the platelet P2Y 12 receptor (14); results of measurements are expressed as absolute P2Y 12 reaction units (PRU) or percentage change of platelet aggregation from baseline: the lower the PRU value, the greater the degree of P2Y 12 receptor inhibition by clopidogrel, and vice versa. Not included in the Verify Now analysis were patients receiving glycoprotein IIb/IIIa inhibitors, which interfere with PRU measurement with this technique (11,14 -16) .
One-month clinical follow-up was obtained by office visit in all study patients. Physicians performing laboratory testing, In-Lab Clopidogrel Loading Versus Routine Pre-Load follow-up assessments, and statistical evaluations were not aware of the randomization assignment. Each patient gave informed consent to the study. The study was approved by the institutional review boards of the institutions involved. End points. The primary end point of the ARMYDA-5 PRELOAD trial was 30-day incidence of MACE (cardiac death, myocardial infarction [MI], target vessel revascularization). MI was defined, following the consensus statement of the Joint European Society of Cardiology/American College of Cardiology Foundation/American Heart Association/World Heart Federation Task Force for the Redefinition of Myocardial Infarction for clinical trials on coronary intervention (17) , as a post-procedural increase of cardiac biomarkers (troponin or creatine kinase-MB) Ͼ3ϫ the 99th percentile of the upper reference limit in patients with normal baseline levels of creatine kinase-MB; in patients with ACS and raised baseline creatine kinase-MB levels, the definition of a subsequent elevation Ն50% the baseline value was applied (18) . Target vessel revascularization included bypass surgery or repeat PCI of the target vessel(s). Secondary end points included: 1) any post-procedural increase of markers of myocardial injury (creatine kinase-MB and troponin-I) above upper normal limits; 2) occurrence of vascular/hemorrhagic complications: a) major bleeding, defined as intracranial bleeding or clinically overt bleeding associated with a decrease in hemoglobin of more than 5 g/dl, according to the Thrombolysis In Myocardial Infarction criteria (19) ; b) minor bleeding (clinically overt hemorrhage associated with a fall in hemoglobin 3 to 5 g/dl); and c) entry-site complications (hematoma Ͼ5 cm [20] , pseudoaneurysm or arteriovenous fistula); and 3) comparison of periprocedural platelet reactivity levels at different time points in the 2 arms. Statistics. For a hypothetical 10% event rate in the preload group (1, 21) , a study population of at least 404 patients (202 per treatment arm) would be needed to detect in the in-lab group a 10.4% absolute increase or a 7.1% reduction in the incidence of 30-day MACE, with an alpha of 0.05 (2-tailed) and beta of 0.8.
Categorical variables are shown as percentages and continuous variables as mean Ϯ SD, unless otherwise specified. Continuous variables between the 2 arms were compared by t test for normally distributed values (as assessed by Kolmogorov-Smirnov test), otherwise the Mann-Whitney U test was used. Proportions were compared by Fisher exact test or chi-square test (Yates corrected) when appropriate. Main outcome measures are reported with 95% confidence intervals (CIs) of the absolute difference and with odds ratios (ORs) with 95% CI, in order to identify the size of possible differences between the 2 strategies (in-lab load vs. pre-load). Event-free survival analysis was performed by the Kaplan-Meier method with log-rank test group comparison. All calculations were performed by SPSS version 15.0 (SPSS Inc., Chicago, Illi- 552
nois), and p values Ͻ0.05 (2-sided) were considered significant.
Results

Study population.
Main clinical and procedural variables in the 2 arms are indicated in Tables 1 and 2 , respectively. In the pre-load arm, clopidogrel was given at a mean of 6.0 Ϯ 0.6 h before intervention. Age, sex, cardiovascular risk factors, clinical presentation, left ventricular function, medical therapy at the time of intervention, renal function, coronary anatomy, and procedural characteristics were similar in the 2 groups. Of note, diabetes mellitus was present in 36% of patients in the in-lab arm and in 33% of those in the pre-load arm, NSTE-ACS in 36% and 43%, respectively, and use of drug-eluting stents in 39% and 35%. Procedural success was obtained in 202 of 205 patients (99%) of the in-lab group and in 201 of 204 patients (99%) of the pre-load arm (p ϭ 0.69); all unsuccessful procedures were due to failure to cross a chronic total occlusion. No procedural side branch (Ն2 mm) closure occurred. No patient died or required emergency CABG surgery.
After diagnostic angiography, 55 patients (n ϭ 28 in the in-lab and n ϭ 27 in the pre-load arms) had an indication for bypass surgery and were excluded from the study; they underwent elective surgical revascularization a mean of 10 days later. In those among them who received pre-load, there was no CABG-related bleeding. Primary end point. Incidence of the primary end point was 8.8% (18 of 205 patients) in the in-lab arm versus 10.3% (21 of 204 patients) in the pre-load arm (p ϭ 0.72) (Fig. 2) . The in-lab rate was 1.5% better than the pre-load rate; the 95% CI for this difference was from 4.1% worse to 6.9% better, corresponding to an OR of 0.84 (95% CI: 0.44 to 1.62). Thirty-day occurrence of MACE was mainly due to periprocedural myocardial infarction in both arms: 8.8% (18 of 205) versus 9.3% (19 of 204) (p ϭ 0.990) (Fig. 3) . In the pre-load group, 1 patient had a sudden death 3 weeks after intervention, and 1 patient received target vessel revascularization with PCI within 1 month due to subacute baremetal stent thrombosis.
A post-hoc subgroup analysis showed no significant MACE difference in patients with ACS (12 of 73, 16% vs. 9 of 87, 10%; p ϭ 0.36) or multivessel PCI (6 of 32, 19% vs. 2 of 30, 7%; p ϭ 0.26) randomized to in-lab load versus pre-load. In ACS patients, CI for the absolute difference in MACE was from 16.6% worse to 4% better using in-lab loading (OR: 1.70, 95% CI: 0.68 to 4.31); for multivessel PCI, OR for in-lab versus pre-load was 3.2 (95% CI: 0.60 to 17.4). In the subgroup with stable angina, MACE occurred in 5% (6 of 132) versus 10% (12 of 117; p ϭ 0.14) of patients, with 95% CI of the absolute difference in events using in-lab loading ranging from 0.7% worse to 12% better and an OR of 0.42 (95% CI: 0.15 to 1.15).
Secondary end points. CARDIAC MARKERS ELEVATION.
There was a similar incidence of post-procedural elevation of creatine kinase-MB above the upper normal limits in the 2 arms (25% in-lab vs. 28% pre-load; p ϭ 0.63); no significant difference was observed in the 2 groups with Di Sciascio et al. August 10, 2010:550-7 In-Lab Clopidogrel Loading Versus Routine Pre-Load regard to increase of troponin-I values above normal limits after intervention (52% vs. 53%; p ϭ 0.80). Distribution of cardiac markers is indicated in Figure 4 .
BLEEDING/VASCULAR COMPLICATIONS.
No patient had post-procedural major bleeding or required transfusions. Minor bleeding was observed in 11 patients (5.4%) of the
Figure 2 Primary Study End Point
Thirty-day occurrence of death, myocardial infarction, target vessel revascularization in patients receiving 600-mg clopidogrel in-lab load or pre-load. MACE ϭ major adverse cardiac events; PCI ϭ percutaneous coronary intervention. 
Figure 3 Individual Components of the Primary End Point
Incidence of adverse events was mainly due to periprocedural myocardial infarction (MI) in both arms. TVR ϭ target vessel revascularization. in-lab arm and in 16 (7.8%) of the pre-load arm (p ϭ 0.42) ( Fig. 5 ): in the former group, 1 patient had urethral bleeding and 10 a groin hematoma Ͼ5 cm; in the latter, 1 patient had urethral and 1 had gum bleeding during glycoprotein IIb/IIIa infusion, and 14 had a groin hematoma Ͼ5 cm.
Procedural Features
PLATELET REACTIVITY. At study entry, PRU levels were comparable in both arms; PRU peak was higher at PCI (p ϭ 0.043) and at 2 h (p ϭ 0.01) in the in-lab arm, and levels progressively decreased in a parallel fashion in both arms and became similar at 8 and 24 h (Fig. 6 ).
Discussion
ARMYDA-5 PRELOAD indicates that 600-mg in-lab loading pre-PCI has similar effects on clinical outcome as a routine 600-mg pre-load in patients undergoing coronary angiography. In particular, loading in the lab after coronary angiography is safe, without increase in ischemic complications, and upstream pre-loading is not associated with excess bleeding, which is recognized as a strong predictor of unfavorable outcome after PCI (22, 23) . Both of those concerns have been discussed in previous studies addressing the indication of routine pre-loading and surgical bleeding after clopidogrel administration. The PRAGUE-8 study (24) evaluated pre-loading versus in-lab strategy in a majority of stable angina patients of whom only 29% underwent PCI, with a trend toward increased minor bleeding, but similar major cardiac events in the pre-load arm. Conversely, our study population included 40% NSTE-ACS, and 80% had PCI after coronary angiography; thus, unlike PRAGUE-8, the large majority of our enrolled cohort had a high likelihood of undergoing PCI, and our results suggest that bleeding rates are not increased when pre-loading is utilized.
ARMYDA-5 PRELOAD shows no significantly different impact on clinical outcome of the 2 strategies; 95% CI for events using in-lab loading ranged from 4.1% worse to 6.9% better, indicating that there is confidence that in-lab is no more than 4.1% higher risk than pre-load.
Is platelet inhibition adequate when an in-lab clopidogrel bolus is given, without several hours pre-loading? No excess ischemic events were observed in the in-lab arm of our study. In particular, concerning stent thrombosis, only 2 cases of subacute stent thrombosis (1 definite ϩ 1 probable) were observed in the pre-load group and none in the in-lab group. When the VerifyNow assay was utilized to evaluate platelet reactivity, lower PRU values were obtained in the pre-load arm at the time of PCI and at 2 h versus in-lab load, but this did not translate into higher event rates in the in-lab versus the upstream strategy. ARMYDA-PRO (Antiplatelet Therapy for Reduction of MYocardial Damage During Angioplasty-Platelet Reactivity Predicts Outcome) and other studies (11, 16, 25) described the relationship between point-of-care measurement of platelet reactivity and clinical outcome. The lack of influence on clinical outcome in ARMYDA-5 PRELOAD may be due both to the similar baseline PRU values in the 2 groups, and to the fact that PRU at the time of PCI and 2-h after, although statistically different in the 2 arms, identify similar risk groups (as described in ARMYDA-PRO for patients with PRU values in the 4th quartile). Moreover, difference in PRU values at the time of PCI reflects the different timing of clopidogrel loading in the 2 arms; this difference disappears early after PCI (PRU values in the 2 arms are similar at 8 h).
In patients who were deemed in need of bypass surgery after coronary angiography, those randomized to pre-load had no excess surgical bleeding, in accordance with recent evidence from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial (26) , suggesting that clopidogrel exposure prior to coronary angiography in ACS patients undergoing bypass surgery a mean of 5 days Di Sciascio et al. August 10, 2010:550-7 In-Lab Clopidogrel Loading Versus Routine Pre-Load after may be associated with lower incidence of 30-day MACE compared with withholding clopidogrel until after angiography, without increase in major bleeding risk. Study limitations. The study enrolled a mixed patient population, including consecutive patients with both stable angina and ACS: subgroup analysis was performed post hoc, not as a pre-specified end point. The number of patients in the ACS subgroup was relatively small, and the confidence intervals of the absolute difference in clinical events using in-lab loading were wide and compatible with an absolute increase up to 16.6% (or a reduction of 4%). Thus, a note of caution should be considered before concluding that in-lab clopidogrel administration is adequate in all cases regardless of clinical presentation.
Conclusions
Thus, from the ARMYDA-5 PRELOAD trial, we can conclude the following: 1) neither periprocedural nor CABG-related bleeding was increased with pre-loading, confirming ACUITY data; 2) platelet inhibition is higher in the pre-load arm, but ischemia protection is still adequate with in-lab loading, without evidence of increased thrombotic risk with high-dose in-lab clopidogrel administration; 3) when needed, the latter strategy can be a safe and effective alternative to pre-treatment given several hours pre-PCI before knowing patients' anatomy; and 4) accurate patients' risk stratification remains crucial for choosing the appropriate loading approach: in low-risk/low PCI probability patients, routine pre-load may be unnecessary, whereas patients in whom PCI is planned or likely, especially those with ACS (27) (28) (29) , may safely be treated with early preloading as recommended by guidelines (30) . Further studies may be needed before the in-lab loading strategy is also extended to this high-risk setting of patients.
